- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05638295
Testen van het gebruik van AMG 510 (Sotorasib) en Panitumumab als een gerichte behandeling voor KRAS G12C Mutant Solid Tumor Cancers (een ComboMATCH-behandelingsonderzoek)
Een gerandomiseerde fase II-studie van AMG 510 (Sotorasib) met of zonder panitumumab bij gevorderde solide tumoren: een behandelingsonderzoek met ComboMATCH
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Verenigde Staten, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
California
-
Los Angeles, California, Verenigde Staten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Verenigde Staten, 90025
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Palo Alto, California, Verenigde Staten, 94304
- VA Palo Alto Health Care System
-
-
Florida
-
Aventura, Florida, Verenigde Staten, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Verenigde Staten, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Verenigde Staten, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Verenigde Staten, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Hollywood, Florida, Verenigde Staten, 33021
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Jacksonville, Florida, Verenigde Staten, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Verenigde Staten, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Verenigde Staten, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Verenigde Staten, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Verenigde Staten, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Verenigde Staten, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Verenigde Staten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Verenigde Staten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Verenigde Staten, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Verenigde Staten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Verenigde Staten, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Verenigde Staten, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Verenigde Staten, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Verenigde Staten, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Verenigde Staten, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Verenigde Staten, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Verenigde Staten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Verenigde Staten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Verenigde Staten, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Verenigde Staten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Verenigde Staten, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Verenigde Staten, 60123
- Advocate Sherman Hospital
-
Hazel Crest, Illinois, Verenigde Staten, 60429
- Advocate South Suburban Hospital
-
Libertyville, Illinois, Verenigde Staten, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Verenigde Staten, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Verenigde Staten, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Verenigde Staten, 60153
- Loyola University Medical Center
-
Normal, Illinois, Verenigde Staten, 61761
- Carle Cancer Institute Normal
-
Normal, Illinois, Verenigde Staten, 61761
- Carle BroMenn Medical Center
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Verenigde Staten, 60453-2699
- Advocate Christ Medical Center
-
Oak Lawn, Illinois, Verenigde Staten, 60453
- Advocate Outpatient Center - Oak Lawn
-
Palos Heights, Illinois, Verenigde Staten, 60463
- Advocate High Tech Medical Park
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Verenigde Staten, 62269
- Memorial Hospital East
-
Springfield, Illinois, Verenigde Staten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Verenigde Staten, 62702
- Springfield Clinic
-
Springfield, Illinois, Verenigde Staten, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Verenigde Staten, 61801
- Carle Cancer Center
-
-
Iowa
-
Ankeny, Iowa, Verenigde Staten, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Verenigde Staten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Verenigde Staten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Verenigde Staten, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Verenigde Staten, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Verenigde Staten, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Verenigde Staten, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Verenigde Staten, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Verenigde Staten, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Verenigde Staten, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Verenigde Staten, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Verenigde Staten, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Verenigde Staten, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Verenigde Staten, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Verenigde Staten, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Verenigde Staten, 48503
- Hurley Medical Center
-
Flint, Michigan, Verenigde Staten, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Verenigde Staten, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Verenigde Staten, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Verenigde Staten, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Verenigde Staten, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Verenigde Staten, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Corewell Health William Beaumont University Hospital
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Corewell Health Children's
-
Saginaw, Michigan, Verenigde Staten, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Verenigde Staten, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Verenigde Staten, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Verenigde Staten, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, Verenigde Staten, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Verenigde Staten, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Verenigde Staten, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Deer River, Minnesota, Verenigde Staten, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Verenigde Staten, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Verenigde Staten, 55746
- Essentia Health Hibbing Clinic
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, Verenigde Staten, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Verenigde Staten, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Verenigde Staten, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Verenigde Staten, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Verenigde Staten, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Verenigde Staten, 63136
- Siteman Cancer Center at Christian Hospital
-
-
Montana
-
Anaconda, Montana, Verenigde Staten, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Verenigde Staten, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Verenigde Staten, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Verenigde Staten, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Verenigde Staten, 59901
- Logan Health Medical Center
-
Missoula, Montana, Verenigde Staten, 59804
- Community Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Verenigde Staten, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Verenigde Staten, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Verenigde Staten, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Verenigde Staten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Verenigde Staten, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Verenigde Staten, 43228
- Doctors Hospital
-
Columbus, Ohio, Verenigde Staten, 43215
- Grant Medical Center
-
Dayton, Ohio, Verenigde Staten, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Verenigde Staten, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Verenigde Staten, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, Verenigde Staten, 43016
- Dublin Methodist Hospital
-
Dublin, Ohio, Verenigde Staten, 43016
- Columbus Oncology and Hematology Associates
-
Kettering, Ohio, Verenigde Staten, 45429
- Kettering Medical Center
-
Mansfield, Ohio, Verenigde Staten, 44903
- OhioHealth Mansfield Hospital
-
Marion, Ohio, Verenigde Staten, 43302
- OhioHealth Marion General Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Verenigde Staten, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Verenigde Staten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Verenigde Staten, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Thomas Jefferson University Hospital
-
Willow Grove, Pennsylvania, Verenigde Staten, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Verenigde Staten, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Verenigde Staten, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Verenigde Staten, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Verenigde Staten, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Verenigde Staten, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Verenigde Staten, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Verenigde Staten, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Verenigde Staten, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, Verenigde Staten, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, Verenigde Staten, 37604
- Regional Cancer Center at Johnson City Medical Center
-
Kingsport, Tennessee, Verenigde Staten, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Verenigde Staten, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Nashville, Tennessee, Verenigde Staten, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Temple, Texas, Verenigde Staten, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Bristol, Virginia, Verenigde Staten, 24201
- Ballad Health Cancer Care - Bristol
-
Charlottesville, Virginia, Verenigde Staten, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Verenigde Staten, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Charleston, West Virginia, Verenigde Staten, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Appleton, Wisconsin, Verenigde Staten, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Verenigde Staten, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Verenigde Staten, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Verenigde Staten, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Verenigde Staten, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Verenigde Staten, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Verenigde Staten, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Verenigde Staten, 54311
- Aurora BayCare Medical Center
-
Janesville, Wisconsin, Verenigde Staten, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kenosha, Wisconsin, Verenigde Staten, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Verenigde Staten, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, Verenigde Staten, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Verenigde Staten, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Verenigde Staten, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Verenigde Staten, 54956
- ThedaCare Regional Medical Center - Neenah
-
New London, Wisconsin, Verenigde Staten, 54961
- ThedaCare Cancer Care - New London
-
Oshkosh, Wisconsin, Verenigde Staten, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Verenigde Staten, 54904
- ThedaCare Cancer Care - Oshkosh
-
Racine, Wisconsin, Verenigde Staten, 53406
- Aurora Cancer Care-Racine
-
Shawano, Wisconsin, Verenigde Staten, 54166
- ThedaCare Cancer Care - Shawano
-
Sheboygan, Wisconsin, Verenigde Staten, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Verenigde Staten, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Verenigde Staten, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waupaca, Wisconsin, Verenigde Staten, 54981
- ThedaCare Cancer Care - Waupaca
-
Wauwatosa, Wisconsin, Verenigde Staten, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Verenigde Staten, 53227
- Aurora West Allis Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
-
Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
-
Patient must be >= 18 years of age
-
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
-
Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
-
Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
-
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)
-
Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization
-
Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible
-
Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption
-
Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis
-
Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition
-
Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab
-
Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)
-
Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)
-
COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
-
COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
-
COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
- NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
-
COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Andere namen:
Undergo collection of blood
Andere namen:
Undergo CT scan
Andere namen:
Undergo tumor biopsy
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
|
|
Actieve vergelijker: Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Andere namen:
Undergo collection of blood
Andere namen:
Undergo CT scan
Andere namen:
Undergo tumor biopsy
Andere namen:
Given PO
Andere namen:
|
|
Experimenteel: Cohort II (sotorasib, panitumumab)
Patients receive combination therapy as in Arm A. |
Undergo MRI
Andere namen:
Undergo collection of blood
Andere namen:
Undergo CT scan
Andere namen:
Undergo tumor biopsy
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS) (Cohort I)
Tijdsspanne: From registration to documented disease progression or death from any cause, assessed up to 3 years
|
PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level. |
From registration to documented disease progression or death from any cause, assessed up to 3 years
|
|
Best objective response (Cohort II)
Tijdsspanne: From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors. |
From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
|
Overall response rate (ORR) (Cohort II)
Tijdsspanne: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used. |
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival (OS) (Cohort I)
Tijdsspanne: Up to 3 years
|
OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported. |
Up to 3 years
|
|
ORR (Cohort I)
Tijdsspanne: Up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
Up to 3 years
|
|
Disease control rates (Cohort I)
Tijdsspanne: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
PFS (Cohort II)
Tijdsspanne: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
|
OS (Cohort II)
Tijdsspanne: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Kristen R Spencer, ECOG-ACRIN Cancer Research Group
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Neoplastische processen
- Pathologische aandoeningen, tekenen en symptomen
- Neoplasma metastase
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Chirurgische procedures, operatief
- Cytologische technieken
- Cytodiagnose
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Diagnostische technieken, chirurgisch
- Chemie -technieken, analytisch
- Spectrumanalyse
- Panitumumab
- Biopsie
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- sotorasib
Andere studie-ID-nummers
- NCI-2022-09876
- U10CA180820 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2022-09876 (Register-ID: CTRP (Clinical Trial Reporting Program))
- EAY191-E5 (Andere identificatie: CTEP)
- EAY191-E5 (Andere identificatie: ECOG-ACRIN Cancer Research Group)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .